Proof-of-concept Study for SAR441344 (Frexalimab) in Relapsing Multiple Sclerosis (NCT04879628)
A Phase 2, Double-blind, Randomized, Placebo-controlled Study Assessing Efficacy and Safety of SAR441344, a CD40L-antagonist Monoclonal Antibody, in Participants With Relapsing Multiple Sclerosis
🩺 Plain-English Summary (8th-Grade Level)
Primary Objective: To determine the efficacy of SAR441344 as measured by reduction of the number of new active brain lesions Secondary Objective: * To evaluate efficacy of SAR441344 on disease activity as assessed by other MRI measures * To evaluate the safety and tolerability of SAR441344 * To evaluate pharmacokinetics of SAR441344
Who can join: Review the eligibility criteria below.
Location: Center for Neurology and Spine- Site Number : 8400007 — Phoenix, Arizona
Age range: 18 Years to 55 Years
🧪 Interventions in This Study
📋 "Do I Qualify?" — 1-Minute Self Screener
Instant ChecklistFull eligibility criteria are available on the official NIH protocol. View the criteria ↗
📍 All Participating Trial Locations (37 Sites)
Showing the first 25 of 37 sites.
- Center for Neurology and Spine- Site Number : 8400007 — Phoenix, Arizona
- University of South Florida Site Number : 8400001 — Tampa, Florida
- The Neurological Institute Site Number : 8400004 — Charlotte, North Carolina
- Medical College of Wisconsin- Site Number : 8400006 — Milwaukee, Wisconsin
- Investigational Site Number : 1000002 — Pleven,
- Investigational Site Number : 1000003 — Sofia,
- Investigational Site Number : 1000001 — Sofia,
- Investigational Site Number : 1240001 — Gatineau, Quebec
- Investigational Site Number : 2030003 — Brno,
- Investigational Site Number : 2030002 — Hradec Králové,
- Investigational Site Number : 2030001 — Jihlava,
- Investigational Site Number : 2030005 — Ostrava - Poruba,
- Investigational Site Number : 2030004 — Teplice,
- Investigational Site Number : 2500006 — Calais,
- Investigational Site Number : 2760012 — Leipzig,
- Investigational Site Number : 2760004 — Münster,
- Investigational Site Number : 6430002 — Kazan',
- Investigational Site Number : 6430007 — Moscow,
- Investigational Site Number : 6430006 — Moscow,
- Investigational Site Number : 6430001 — Moscow,
- Investigational Site Number : 6430003 — Saint Petersburg,
- Investigational Site Number : 6430005 — Saint Petersburg,
- Investigational Site Number : 6430004 — Saint Petersburg,
- Investigational Site Number : 6430008 — Tyumen,
- Investigational Site Number : 7240004 — Barcelona, Barcelona [Barcelona]
💰 Cost, Insurance & Patient Rights
- 100% Free Items: The investigational treatment and protocol-required procedures are supplied at zero cost by the sponsor.
- Routine Patient Care: Under federal law (ACA § 2709) and many state statutes, routine care costs are covered during participation.
- Voluntary Participation: You may withdraw at any time without affecting your standard medical care.
More studies in Multiple Sclerosis
- Safety and Efficacy of Fingolimod in Pediatric Patients With Multiple Sclerosis — Birmingham, Alabama
- MSCopilot Users' Feedback in Real Life - Outcomes Regarding Integration in Patients' pathWay and Users' ExpeRience — New Orleans, Louisiana
- A Rollover Study to Evaluate the Long-Term Safety and Efficacy of Ocrelizumab In Patients With Multiple Sclerosis — Phoenix, Arizona
- A Study to Assess Bioequivalence of Two Subcutaneous (SC) Formulations of Ocrelizumab in Participants With Multiple Sclerosis (MS) — Carlsbad, California
- The Synergistic Effects of AIH and FES in Persons With MS — Chicago, Illinois
- A Health Action Process Approach Online Intervention for People With Multiple Sclerosis — Champaign, Illinois
Explore by condition: All Multiple Sclerosis clinical trials
💡 How to Participate
- Check the checklist above to see if you may qualify.
- Review the official NIH record below to find the coordinating site.
- Ask about the visit schedule, what is covered at no cost, and any travel support.
- Confirm with your own doctor before making a decision.